March 3, 2021 -- AGC Biologics said its plans to expand its cell and gene therapy center of excellence in Milan to increase and implement viral vector suspension capabilities.
The expansion will include the addition of two floors to its existing suite and installation of additional equipment on the current floor. The new facilities are slated to begin operations in 2022.
The investment in the expansion is part of the contract development and manufacturing organization (CDMO)'s plan to grow cell and gene therapy (CGT) capabilities around the world, according to AGC.
This announcement follows AGC's acquisition and integration of the MolMed facilities in Italy less than one year ago. The Milan site was the first good manufacturing practice (GMP) facility approved in Europe for ex vivo gene therapy manufacturing and has experience with two commercial CGT products.
With this, AGC is one of the only CDMOs offering plasmid production and end-to-end CGT services.
Copyright © 2021 scienceboard.net